Answers are grounded in this paper and cite their sources.
Fluoroquinolones (FQ) are widely used in the treatment of community-acquired pneumonia (CAP) in certain cases specified in Russian clinical guidelines. However, FQ are known to have cardiotoxic effects. There have been reports on proarrhythmogenic effect of this drug class, which is more often presented as QT prolongation and may lead to the development of “torsade de pointes” and ventricular fibrillation. Adverse effects of FQ on aortic wall leading to the formation of aneurysm are also reported. Given the above, treatment of CAP in patients with chronic heart failure is challenging. This paper provides a review of clinical pharmacology of FQ, their role in the treatment of CAP, general issues related to cardiotoxicity as well as possible cardiotoxic manifestations of this antibiotic class.
No takes yet. Share an insight, caveat, or question.
Gamayunov et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: